{"nctId":"NCT02171130","briefTitle":"Clinical Usability of Intranasal Glucagon in Treatment of Hypoglycemia","startDateStruct":{"date":"2014-05"},"conditions":["Hypoglycemia","Diabetes Mellitus","Drug-Specific Antibodies"],"count":129,"armGroups":[{"label":"Nasal glucagon","type":"EXPERIMENTAL","interventionNames":["Drug: Nasal Glucagon"]}],"interventions":[{"name":"Nasal Glucagon","otherNames":["Dry-Mist Nasal Glucagon","AMG504-1","LY900018"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Male or Female Person with diabetes (PWD) lives with or is in frequent contact with one or more caregivers who are available to administer the glucagon in case of an episode of severe or moderate hypoglycemia\n* With a history of type 1 diabetes \\>1 year\n* At least 18 years of age but not older than 75 years\n* Body mass index (BMI) greater than or equal to 18.50 and below 35.00 kg/m2.\n* PWD will be otherwise healthy according to medical history, general physical examination (including vital signs), nasal examination, and laboratory tests (biochemistry, hematology, and urinalysis).\n* For female subjects, a urine pregnancy test must be negative.\n\nExclusion Criteria:\n\n* Presence or history of pheochromocytoma (i.e. adrenal gland tumor) or insulinoma.\n* Use of a daily systemic beta-blockers, indomethacin, warfarin or anticholinergic drugs.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"75 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percentage of Participants Awakening or Returning to a Normal Status Within 30 Minutes Following Studied Drug of Administration","description":"Responses to questions completed by the caregiver were used to assess this outcome.\n\nAn episode of severe hypoglycemia was defined as an episode wherein the person with diabetes is clinically incapacitated to the point where the person requires third-party assistance to treat the hypoglycemia. An episode of moderate hypoglycemia episode was defined as an episode wherein the person with diabetes was showing signs of neuroglycopenia and had a glucometer reading of approximately 60 milligrams per deciliter (mg/dL) (3.3 millimoles per liter \\[mmol/L\\]) or less based on a blood sample taken at or near the time of treatment.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"95.7","spread":null}]}]}]},{"type":"SECONDARY","title":"Assessment of Ease-of-use of Dry-Mist Nasal Glucagon as Determined by Completion of Questionnaires by the Caregiver","description":"Measurement for Degree of difficulty: opening the kit, Degree of difficulty: understanding the instructions on how to use the kit, Degree of difficulty: administering the medication into the nostril, Degree of satisfaction is 1 (Very Difficult) to 7 (Very Easy). Measurement for Dry Mist Nasal Glucagon will be easy to teach other caregivers, Nasal formulation of glucagon is less intimidating for caregivers, Nasal Glucagon is easy to carry and would be willing to carry it, nasal delivery of glucagon is preferable. Level of agreement 1 (Strongly Disagree) to 7 (Strongly Agree).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"26","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"143","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"10","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"36","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"127","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"16","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"42","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"102","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"126","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"40","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"21","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"48","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"108","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"47","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"20","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"47","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"127","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Adverse Events (AEs) Reported Through the Nasal Score Questionnaire","description":"Adverse events solicited through the Nasal Score Questionnaire included: runny nose, nasal congestion (nostrils plugged), nasal itching, sneezing, watery eyes, itchy eyes, redness of eyes, itching of ears, itching of throat, and other.\n\nA summary of other nonserious AEs, and all Serious Adverse Events (SAEs), regardless of causality, is located in the Reported Adverse Events section.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"82.8","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Blood Glucose Levels Over Time","description":"The participants' blood glucose level was measured by the caregiver using a glucometer at baseline (just prior to dosing and right after the study drug administration), 15, 30 and 45 minutes after nasal glucagon administration.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"47.9","spread":"10.47"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"84.4","spread":"24.68"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"112.8","spread":"34.33"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"123.1","spread":"38.82"}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Number of Participants With Treatment-Emergent Glucagon Anti-Drug Antibodies (ADA)","description":"Treatment-Emergent ADA includes treatment-induced ADA ('Not Detected' ADA at baseline and at least one post-baseline 'Detected' ADA sample with a corresponding titer of (1:20) and treatment-boosted ADA (with 'Detected' ADA at baseline and at least one post-baseline 'Detected' ADA sample with a corresponding titer that is at least 4-fold higher than the baseline titer.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":1,"n":87},"commonTop":["Nasal Irritation","Headache","Nausea","Lacrimation increased","Vomiting"]}}}